With an IPO, not only the company but also the leadership team goes public; in particular the Chairman, the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO). Interest in the company and the behavior of the management gains a new dimension in terms of public attention. This is why it is so important to take a close look at corporate governance and related topics regarding public relations and establish guidelines and measures that are conducive to the successful management of a company at an early stage.
Relationship Manager Primary Markets, SIX
Alongside the technical aspects of corporate governance – mechanisms, processes and relations with which companies are managed and controlled – there are a number of specific challenges for the leadership team, particularly when it comes to public companies, which are related to corporate governance but have no precise boundaries. Top managers often become the screen on which a multitude of expectations, both within and outside the company, are projected. How to deal with it? Is it possible to escape from the media and the public? Or should you get involved, fully aware of the fine line between hero and bogeyman?
Due to the increased need for transparency, the leaders of a public company are the focal point for public interest. A certain inviolability, which was considered a given in earlier times, is nowadays critically questioned. Currently, of particular interest to the public and especially the press, are remuneration models and the associated expectations regarding social responsibility. For example, it is very difficult to understand how, when employees are laid off, the bonus-pool allocated to top management can simultaneously increase.
Merging of personal and professional
In the age of social media, information is received and shared much faster and more easily. A good example is the use of twitter to comment and share views on experience. The challenge here is to craft communications so that information is correctly received and understood thereby avoiding a maelstrom of bad press and possibly more serious consequences for the individual or organization. For example, customers no longer write a private letter of complaint to a company but instead make public their dissatisfaction with a product or service on twitter. Complicating the situation further is the fact that such information may be true but could also be fake. Success is all about coping with these communications in an effective and timely manner.
Another challenge is that reporting for professional reasons has widened its remit and now encompasses increased interest in (and expectations of) the behavior of individuals in a private capacity. The CEO in particular needs to be acutely aware of public expectations regardless of whether these are businessrelevant activities or private concerns, or to what extent this may or may not be justified. There is now a clear expectation on people in such positions. A CEO must set an example within his or her company and also in public. A modest appearance and/or social commitment may be recognized in the form of a benevolent public response.
Giacomo Di Nepi CEO Polyphor
Have the requirements and your own expectations of a leader changed since becoming CEO of a listed company, or during the IPO process itself?
I think that a few things have changed, mainly with regards to the requirements of a listed company, but possibly less than what could be the case for other companies going through a similar process. The fact that we already had more than 500 shareholders before the IPO helped us a lot when it came to having a somewhat smooth transition. For instance, this meant that we were familiar with AGMs (Annual General Meetings), results’ teleconferences and business progress updates and the provision of equal and transparent information to all shareholders.
Also, the ‘ethics of performance’ have not changed: we need to deliver on our targets, provide a collaborative work environment to succeed as a team and push the organization towards ambitious but achievable goals. And, most importantly, we need to deliver innovative new medicines that provide substantial benefit for patients in need as this is the ultimate mission of our company.
What has changed as a public company are the regulatory requirements with which we must comply with. This increases the sensitivity of our corporate communication and has an impact on our investor relations strategy; this must be more explicit and elaborated and requires a proper allocation of management time and attention.
What has changed for you when you evaluate your leadership style before and after the IPO?
This question you had better asked my colleagues… seriously now, I didn’t change my leadership style. As I mentioned before, we had already implemented our performance management system and our values as a private company. This of course hasn’t changed during the IPO process. The one thing however that I am reminding everyone over and over again is the need to give equal and transparent information to all shareholders and therefore the need to be very careful in what we say externally. This was true also before but now the need is even greater.
Were you aware of the leadership challenges post IPO, and how did you prepare e.g. trainings, studies?
Most of my professional experience has been in public companies so I already knew what would be awaiting me. My last experience with InterMune, as General Manager Europe, was of particular importance. Europe has been ‘the story’ for almost three years as Esbriet, our product for idiopathic pulmonary fibrosis was launched in Europe before the US. Europe was the ‘beta test’ for the expected launch in the US, which happened a few years later. I learned there how to provide factual, equal and transparent information while ‘telling the story’. Paraphrasing the motto of a well-known agency, giving ‘the truth well told’. What is specific to the biotech sector, including Polyphor, is that we have to deal with small companies in a high-stake business and therefore many more things may be material information. For example, a change in a single research or clinical program would be non-material for a Novartis or a Roche, but it would be very much for us.
This further increases my and our whole organization’s responsibility, when it comes to how we deal with information. One week after the IPO we conducted a training with the whole organization, explaining what it means to be a public company. I took this opportunity to provide some practical examples and I’m planning to do a ‘second shot’ of training this year. It’s based on a principle similar to a vaccination, where you really want to have a full, continuous and extended coverage. As we say in marketing language, ‘repetition is the mother of retention!’.
In retrospect, would you do something different and if so, what?
The IPO process is very intense and extremely time-consuming, which can be very challenging for a small organization. It is almost unavoidable that some of the operations and the organization get a bit neglected. Therefore, I think it is very important to plan for a full immersion period after the IPO to make sure all the operations and the organization get the necessary attention and make sure that responsibilities, timelines, and deliverables for each project are clear and properly tackled. In other words… don’t think that after the IPO you can get some rest. Wrong assumption!
Do you have any recommendations for CEOs of future listed companies?
Probably the usual recommendations! Make sure that the equity story and the value creation potential is well documented, clear and understandable. Make sure, test it again and again, and adapt where needed. Get a top team, internally as well as externally, to be well prepared for what will come. Learn quickly to manage the different stakeholders involved and be prepared to hold your nerve because until the end, you do not know what will be the real result. But, as we know, biotech is not for the faint of heart, so… we were well trained!
Ad Hoc Publicity
In the context of ad hoc publicity, the obligation to disclose information relates to potentially price-sensitive facts that have arisen in the sphere of activity of a listed company and are not in the public domain. The following parties must be informed as a bare minimum:
Examples of price-sensitive facts are:
Directive on Ad hoc Publicity: www.six-exchange-regulation.com/dam/downloads/regulation/admission-manual/directives/06_17-DAH_en.pdf
The legal basis and further information can be found at the following address: www.six-exchange-regulation.com/adhoc_publicity
You can send ad hoc notices to us simply and efficiently by e-mail to firstname.lastname@example.org